It is accepted that hERG IC 50 values under manual patch conditions are reasonable surrogate predictors of QT prolongation in vivo, including in humans. In this regard, Redfern et al 1 have offered some guidelines regarding what might be deemed an appropriate therapeutic index (TI) to mitigate the risk of hERG-mediated arrhythmias for clinical candidates. Regardless of the actual TI desired, there is, at times, a degree of confusion regarding how to calculate this value given the different units oftentimes ascribed to an IC 50 value versus those used to reference drug plasma concentrations. Moreover, how to account for free plasma concentrations (also referred to as fraction unbound or free fraction), which represents the amount of circulating compound that is biologically active (eg, not bound to albumin or other blood proteins), might not be obvious to the interested clinician. Thus, offered below is a short primer to the topic that uses haloperidol as an example and makes the following assumptions: (1) the compound is 92% plasma protein bound in humans, 2 (2) the hERG IC 50 value ¼ 0.025 mM, 3 and (3) the human clinical C max is approximately 25 ng/mL. 2 First, plasma drug concentrations normally expressed in ng/ mL or mg/mL need to be converted into a molar value because most hERG IC 50 values are also expressed in mM (hint: mM and mM/L can be considered equivalent units). If the plasma concentration of haloperidol at C max ¼ 25 ng/mL, the molar value can be easily calculated using the molecular weight (MW ¼ 375.85) as the following: 25 ng/mL ÷ 375.85 ¼ 0.0665 mM (66.5 nM). The MW of most compounds can be queried online; an important consideration is to ensure that the MW used in the calculation does not include the weight of any associated salt (eg, haloperidol decanoate has an MW of 530.11, reflecting the addition of the decanoic acid), as the salt generally dissociates upon entry into the blood and is not measured in the plasma. Thus, the equation boils down to mM ¼ ng/mL ÷ free base MW, or mM ¼ (mg/mL ÷ free base MW) * 1000.
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If one wishes to establish a TI relative to a hERG IC 50 based on total drug concentrations in the blood, simply divide the hERG IC 50 value (0.025 mM) by the C max blood concentration also expressed in mM: 0.025 mM / 0.0665 mM ¼ TI < 1X. If, however, one wishes to establish a TI based on free plasma concentrations, the degree of plasma protein binding must be built into the calculation. In the case of haloperidol that is 92% plasma protein bound (8% free, or 0.08), the free concentration at C max ¼ 0.0665 mM * 0.08 ¼ 0.005 mM (5 nM). In this example, the TI relative to a hERG IC 50 based on fraction unbound ¼ 0.025 mM / 0.005 mM ¼ 5X, a margin consistent with a category 3 drug (as defined by Redfern et al 1 ) with a measurable incidence of torsades de pointes in humans and a margin below that deemed acceptable for most new chemical entities entering first-in-human clinical trials for nondebilitating diseases.
Fitting all of the pieces together, a TI relative to the hERG IC 50 and unbound plasma concentrations at C max can be calculated as TI ¼ mM hERG IC 50 / [(ng/mL at C max ÷ free base MW) * free fraction].
Declaration of Conflicting Interests
The author declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The author is employed by Boehringer-Ingelheim Pharmaceuticals Inc.
